Analyst Consensus ?
ConsensusBuy56 ratings
Bullish4885.7%
Neutral712.5%
Bearish11.8%
FN2 Earnings Intelligence
Vertex Pharmaceuticals Incorporated complete analyst coverage
Vertex Pharmaceuticals Incorporated (VRTX) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$517.49Previous close
$175Low
$476.98Average
$665High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Outperform | Outperform | Maintain | Oct 8, 2026 |
| UBS | Buy | Buy | Maintain | Sep 28, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 5, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 5, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 4, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Aug 4, 2026 |
| Canaccord Genuity | Hold | Hold | Maintain | Aug 4, 2026 |
| Baird | Underperform | Underperform | Maintain | Jul 7, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 5, 2026 |
| Bernstein | Outperform | Outperform | Maintain | May 5, 2026 |
| Maxim Group | Buy | Hold | Upgrade | Mar 18, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Mar 10, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Mar 10, 2026 |
| Citigroup | Buy | Buy | Maintain | Mar 10, 2026 |
| B of A Securities | Buy | Buy | Maintain | Mar 10, 2026 |
| HC Wainwright& Co. | Buy | Buy | Maintain | Feb 17, 2026 |
| Stifel | Hold | Hold | Maintain | Feb 13, 2026 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | Feb 13, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jan 23, 2026 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jan 6, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Dec 29, 2025 |
| Wells Fargo | Overweight | Overweight | Maintain | Dec 10, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 8, 2025 |
| Guggenheim | Buy | Buy | Maintain | Aug 6, 2025 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 5, 2025 |
| Needham | Hold | Hold | Maintain | May 6, 2025 |
| Piper Sandler | Overweight | Overweight | Maintain | Jan 27, 2025 |
| Jefferies | Buy | Hold | Upgrade | Dec 9, 2024 |
| Argus Research | Buy | Buy | Maintain | Jun 17, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 31, 2024 |
| William Blair | Outperform | Outperform | Maintain | May 30, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Feb 8, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jun 13, 2022 |
| Raymond James | Perform | Market Perform | Maintain | Jul 1, 2021 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 2, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jun 24, 2020 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Apr 30, 2020 |
| CFRA | Buy | Buy | Maintain | Apr 30, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jan 31, 2020 |
| PiperJaffray | Overweight | Overweight | Maintain | Jan 6, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 20, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Oct 31, 2019 |
| H.C. Wainwright | Buy | Neutral | Upgrade | Oct 26, 2018 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| Deutsche Bank | Buy | Buy | Maintain | Dec 13, 2017 |
| DA Davidson | Buy | Buy | Maintain | Sep 29, 2017 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Jul 19, 2017 |
| Janney Capital | Buy | Neutral | Upgrade | Jul 19, 2017 |
| Leerink Swann | Outperform | Outperform | Maintain | Mar 8, 2016 |
| BTIG Research | Buy | Buy | Maintain | Jan 6, 2015 |
| Summer Street | Neutral | Buy | Downgrade | Oct 30, 2013 |
| Wunderlich | Buy | Buy | Maintain | May 17, 2013 |
| Lazard | Neutral | Buy | Downgrade | Jan 15, 2013 |
| Brean Capital | Buy | Hold | Upgrade | May 8, 2012 |
| ISI Group | Buy | Neutral | Upgrade | May 7, 2012 |
| Bank oferica | Buy | Buy | Maintain | Mar 14, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $517.49. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Analyst unavailable | $576 | $502.62 | +11.3% | Oct 8, 2026 |
| UBS | Analyst unavailable | $615 | $528.04 | +18.8% | Sep 28, 2026 |
| Jefferies | Akash Tewari | $640 | $514.99 | +23.7% | Sep 23, 2026 |
| H.C. Wainwright | Andrew Fein | $641 | $519.67 | +23.9% | Sep 22, 2026 |
| Morgan Stanley | Terence Flynn | $665 | $547.65 | +28.5% | Sep 1, 2026 |
| Goldman Sachs | Analyst unavailable | $653 | $544.52 | +26.2% | Sep 1, 2026 |
| Bernstein | Jeffrey Walch | $608 | $530.29 | +17.5% | Aug 11, 2026 |
| Wolfe Research | Andy Chen | $562 | $522.78 | +8.6% | Aug 10, 2026 |
| Truist Financial | Analyst unavailable | $565 | $488.56 | +9.2% | Aug 5, 2026 |
| Barclays | Analyst unavailable | $617 | $478.7 | +19.2% | Aug 5, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $595 | $470.72 | +15.0% | Aug 4, 2026 |
| Canaccord Genuity | Analyst unavailable | $442 | $470.72 | -14.6% | Aug 4, 2026 |
| Stifel Nicolaus | Analyst unavailable | $500 | $470.72 | -3.4% | Aug 4, 2026 |
| UBS | Analyst unavailable | $585 | $481.7 | +13.0% | Jul 13, 2026 |
| Truist Financial | Analyst unavailable | $560 | $479.02 | +8.2% | Jul 13, 2026 |
| RBC Capital | Analyst unavailable | $570 | $529.59 | +10.1% | Jul 7, 2026 |
| Robert W. Baird | Analyst unavailable | $350 | $529.59 | -32.4% | Jul 7, 2026 |
| Truist Financial | Danielle Brill | $542 | $435.93 | +4.7% | May 27, 2026 |
| Barclays | Analyst unavailable | $615 | $424.36 | +18.8% | May 6, 2026 |
| Morgan Stanley | Analyst unavailable | $616 | $417.72 | +19.0% | May 5, 2026 |
| RBC Capital | Brian Abrahams | $543 | $429.85 | +4.9% | May 5, 2026 |
| Bernstein | Analyst unavailable | $572 | $429.85 | +10.5% | May 5, 2026 |
| Canaccord Genuity | Analyst unavailable | $436 | $429.85 | -15.7% | May 5, 2026 |
| Canaccord Genuity | Analyst unavailable | $437 | $423.24 | -15.6% | Apr 30, 2026 |
| Morgan Stanley | Analyst unavailable | $612 | $436.89 | +18.3% | Apr 10, 2026 |
| Truist Financial | Joon Lee | $525 | $499.14 | +1.5% | Mar 10, 2026 |
| Jefferies | Akash Tewari | $580 | $496.5 | +12.1% | Mar 10, 2026 |
| BMO Capital | Evan David Seigerman | $600 | $487.57 | +15.9% | Mar 2, 2026 |
| Canaccord Genuity | Analyst unavailable | $441 | $491.47 | -14.8% | Feb 17, 2026 |
| Barclays | Eliana Merle | $607 | $491.47 | +17.3% | Feb 17, 2026 |
| H.C. Wainwright | Andrew Fein | $591 | $491.47 | +14.2% | Feb 17, 2026 |
| Morgan Stanley | Terence Flynn | $570 | $497.42 | +10.1% | Feb 13, 2026 |
| Scotiabank | Louise Chen | $558 | $493.98 | +7.8% | Feb 13, 2026 |
| RBC Capital | Analyst unavailable | $541 | $496.02 | +4.5% | Feb 13, 2026 |
| Bernstein | Analyst unavailable | $577 | $497.21 | +11.5% | Feb 13, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $590 | $495.11 | +14.0% | Feb 13, 2026 |
| Stifel Nicolaus | Paul Matteis | $466 | $465.02 | -9.9% | Feb 13, 2026 |
| H.C. Wainwright | Andrew Fein | $518 | $465.02 | +0.1% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $606 | $474.17 | +17.1% | Jan 27, 2026 |
| UBS | Analyst unavailable | $545 | $474.09 | +5.3% | Jan 26, 2026 |
| Evercore ISI | Cory Kasimov | $530 | $469.11 | +2.4% | Jan 23, 2026 |
| RBC Capital | Brian Abrahams | $546 | $461.14 | +5.5% | Jan 22, 2026 |
| UBS | Michael Yee | $535 | $468.38 | +3.4% | Jan 6, 2026 |
| Leerink Partners | Analyst unavailable | $525 | $462.12 | +1.5% | Dec 29, 2025 |
| Morgan Stanley | Analyst unavailable | $564 | $461.48 | +9.0% | Dec 5, 2025 |
| Morgan Stanley | Terence Flynn | $516 | $433.15 | -0.3% | Dec 3, 2025 |
| RBC Capital | Analyst unavailable | $415 | $426.93 | -19.8% | Nov 4, 2025 |
| Cantor Fitzgerald | Carter Gould | $485 | $427.3 | -6.3% | Nov 4, 2025 |
| Stifel Nicolaus | Analyst unavailable | $445 | $426 | -14.0% | Nov 4, 2025 |
| Barclays | Gena Wang | $414 | $426 | -20.0% | Nov 4, 2025 |
| Morgan Stanley | Analyst unavailable | $438 | $413.93 | -15.4% | Oct 10, 2025 |
| Leerink Partners | Analyst unavailable | $456 | $381.87 | -11.9% | Sep 25, 2025 |
| Truist Financial | Analyst unavailable | $490 | $374.98 | -5.3% | Aug 5, 2025 |
| Stifel Nicolaus | Analyst unavailable | $455 | $374.98 | -12.1% | Aug 5, 2025 |
| UBS | Eliana Merle | $553 | $374.98 | +6.9% | Aug 5, 2025 |
| BMO Capital | Analyst unavailable | $530 | $374.98 | +2.4% | Aug 5, 2025 |
| H.C. Wainwright | Analyst unavailable | $478 | $374.98 | -7.6% | Aug 5, 2025 |
| Morgan Stanley | Analyst unavailable | $439 | $374.98 | -15.2% | Aug 5, 2025 |
| RBC Capital | Brian Abrahams | $420 | $441.99 | -18.8% | Jun 17, 2025 |
| Scotiabank | Greg Harrison | $442 | $450.03 | -14.6% | May 6, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $535 | $490.47 | +3.4% | Apr 22, 2025 |
| BMO Capital | Evan Seigerman | $545 | $461.68 | +5.3% | Jan 31, 2025 |
| Wells Fargo | Mohit Bansal | $460 | $441.52 | -11.1% | Jan 30, 2025 |
| Morgan Stanley | Terence Flynn | $456 | $409.56 | -11.9% | Jan 10, 2025 |
| RBC Capital | Brian Abrahams | $400 | $469.22 | -22.7% | Dec 19, 2024 |
| Jefferies | Michael Yee | $550 | $462.1 | +6.3% | Dec 9, 2024 |
| Oppenheimer | Hartaj Singh | $540 | $499.1 | +4.3% | Nov 5, 2024 |
| RBC Capital | Brian Abrahams | $451 | $499.88 | -12.8% | Nov 5, 2024 |
| Canaccord Genuity | Whitney Ijem | $361 | $478.09 | -30.2% | Oct 22, 2024 |
| BMO Capital | Evan David Seigerman | $566 | $485.74 | +9.4% | Oct 21, 2024 |
| Goldman Sachs | Salveen Richter | $598 | $483 | +15.6% | Oct 21, 2024 |
| Bank of America Securities | Geoff Meacham | $541 | $482.12 | +4.5% | Oct 14, 2024 |
| RBC Capital | Brian Abrahams | $437 | $458.94 | -15.6% | Oct 9, 2024 |
| Truist Financial | Joon Lee | $550 | $494.46 | +6.3% | Aug 5, 2024 |
| Oppenheimer | Hartaj Singh | $550 | $477.86 | +6.3% | Aug 5, 2024 |
| Wolfe Research | Andy Chen | $576 | $476.91 | +11.3% | Aug 5, 2024 |
| H.C. Wainwright | Andrew Fein | $600 | $505.78 | +15.9% | Aug 2, 2024 |
| Argus Research | Jasper Hellweg | $550 | $474.61 | +6.3% | Jun 17, 2024 |
| RBC Capital | Brian Abrahams | $421 | $483.28 | -18.6% | Jun 11, 2024 |
| BMO Capital | Evan David Seigerman | $500 | $443.05 | -3.4% | May 31, 2024 |
| Raymond James | Christopher Raymond | $456 | $413.42 | -11.9% | May 7, 2024 |
| RBC Capital | Brian Abrahams | $424 | $402.5 | -18.1% | May 7, 2024 |
| H.C. Wainwright | Andrew Fein | $462 | $397.58 | -10.7% | Apr 11, 2024 |
| Evercore ISI | Liisa Bayko | $438 | $397.58 | -15.4% | Apr 11, 2024 |
| Morgan Stanley | Analyst unavailable | $285 | $297.18 | -44.9% | Feb 8, 2023 |
| H.C. Wainwright | Analyst unavailable | $326 | $308.54 | -37.0% | Feb 8, 2023 |
| Leerink Partners | Analyst unavailable | $365 | $308.54 | -29.5% | Feb 8, 2023 |
| Argus Research | Analyst unavailable | $340 | $310.86 | -34.3% | Nov 17, 2022 |
| Morgan Stanley | Analyst unavailable | $253 | $290.68 | -51.1% | Aug 8, 2022 |
| H.C. Wainwright | Analyst unavailable | $300 | $279.54 | -42.0% | Aug 5, 2022 |
| Cantor Fitzgerald | Olivia Brayer | $365 | $290.01 | -29.5% | Jul 12, 2022 |
| Stifel Nicolaus | Paul Matteis | $240 | $295.46 | -53.6% | Jul 11, 2022 |
| Argus Research | Jasper Hellweg | $280 | $287.32 | -45.9% | Jul 2, 2022 |
| Cowen & Co. | Analyst unavailable | $310 | $248.96 | -40.1% | Jun 13, 2022 |
| Morgan Stanley | Matthew Harrison | $250 | $261.96 | -51.7% | May 3, 2022 |
| Piper Sandler | Analyst unavailable | $249 | $279.02 | -51.9% | Apr 22, 2022 |
| Oppenheimer | Hartaj Singh | $350 | $272.39 | -32.4% | Apr 6, 2022 |
| Robert W. Baird | Brian Skorney | $240 | $251.88 | -53.6% | Mar 22, 2022 |
| BMO Capital | Evan Seigerman | $274 | $251.88 | -47.1% | Mar 22, 2022 |
| Jefferies | Michael Yee | $275 | $228.22 | -46.9% | Jan 27, 2022 |
| Wolfe Research | Andrew Galler | $282 | $228.22 | -45.5% | Jan 27, 2022 |
| J.P. Morgan | Cory Kasimov | $288 | $228.22 | -44.3% | Jan 27, 2022 |
| Morgan Stanley | Matthew Harrison | $208 | $228.22 | -59.8% | Jan 27, 2022 |
| Cowen & Co. | Phil Nadeau | $300 | $229.68 | -42.0% | Jan 24, 2022 |
| Leerink Partners | Geoff Porges | $175 | $204.45 | -66.2% | Dec 2, 2021 |
| Guggenheim | Debjit Chattopadhyay | $286 | $205 | -44.7% | Dec 1, 2021 |
| Bank of America Securities | Geoff Meacham | $275 | $181.4 | -46.9% | Nov 2, 2021 |
| Cantor Fitzgerald | Alethia Young | $281 | $193.02 | -45.7% | Jun 11, 2021 |
| Barclays | Gena Wang | $285 | $193.02 | -44.9% | Jun 11, 2021 |
| UBS | Colin Bristow | $279 | $212.68 | -46.1% | May 12, 2021 |
Track every rating change on VRTX the moment it posts. Free to start.
Start freeGet the VRTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.